Compare HBIO & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | AYTU |
|---|---|---|
| Founded | 1901 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 27.4M |
| IPO Year | 2000 | 2015 |
| Metric | HBIO | AYTU |
|---|---|---|
| Price | $7.93 | $2.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $18.00 | $9.33 |
| AVG Volume (30 Days) | 19.3K | ★ 31.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,176,000.00 | $27,632,080.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.38 | $1.65 |
| 52 Week High | $7.90 | $3.07 |
| Indicator | HBIO | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 78.01 | 49.18 |
| Support Level | $5.91 | $2.08 |
| Resistance Level | N/A | $2.32 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 100.00 | 29.54 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.